GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Forward PE Ratio

Nephros (Nephros) Forward PE Ratio : 0.00 (As of May. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nephros Forward PE Ratio?

Nephros's Forward PE Ratio for today is 0.00.

Nephros's PE Ratio without NRI for today is 0.00.

Nephros's PE Ratio for today is 0.00.


Nephros Forward PE Ratio Historical Data

The historical data trend for Nephros's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Forward PE Ratio Chart

Nephros Annual Data
Trend
Forward PE Ratio

Nephros Quarterly Data
Forward PE Ratio

Competitive Comparison of Nephros's Forward PE Ratio

For the Medical Instruments & Supplies subindustry, Nephros's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nephros's Forward PE Ratio falls into.



Nephros Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Nephros  (NAS:NEPH) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Nephros Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nephros's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros (Nephros) Business Description

Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.
Executives
Banks Robert R. Jr. director, officer: President and CEO C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel officer: Chief Financial Officer 320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo officer: Chief Marketing Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor officer: Chief Financial Officer 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp director, 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino officer: Chief Financial Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans director, officer: President and CEO C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830

Nephros (Nephros) Headlines

From GuruFocus

Nephros Announces Results for Quarter Ended March 31, 2023

By sperokesalga sperokesalga 05-10-2023

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 07-06-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 06-16-2022

Nephros Announces Results for Quarter Ended June 30, 2022

By PurpleRose PurpleRose 08-10-2022

Nephros First Quarter 2022 Financial Results Conference Call

By GuruFocusNews GuruFocusNews 04-27-2022

Nephros Fourth Quarter 2021 Financial Results Conference Call

By GuruFocusNews GuruFocusNews 02-09-2022

Nephros Issues 2022 Shareholder Letter

By GuruFocusNews GuruFocusNews 01-13-2022